An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →. With Pfizer.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
65actual
Sites
26
Countries
Israel, Japan, South Korea +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic considerations
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-02-13 | actual | When the study began enrolling |
| Primary completion | 2026-05-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-07 | actual | The whole study's end, after follow-up |
| First posted | 2019-12-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cancer
- Non-small Cell Lung Cancer (NSCLC)
Intervention
- Drug: Cofetuzumab Pelidotin — also filed as ABBV-647
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR)
measured Up to approximately 3 years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed